{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"194","upperLimit":"393","value":"281"},{"groupId":"OG001","lowerLimit":"174","upperLimit":"451","value":"329"},{"groupId":"OG002","lowerLimit":"141","upperLimit":"260","value":"169"},{"groupId":"OG003","lowerLimit":"100","upperLimit":"1454","value":"225"},{"groupId":"OG004","lowerLimit":"169","upperLimit":"312","value":"176"},{"comment":"The upper limit of the confidence interval is not estimated due to insufficient number of participants with events.","groupId":"OG005","lowerLimit":"111","upperLimit":"NA","value":"282"},{"comment":"The upper limit of the confidence interval is not estimated due to insufficient number of participants with events.","groupId":"OG006","lowerLimit":"169","upperLimit":"NA","value":"314"},{"groupId":"OG007","lowerLimit":"169","upperLimit":"224","value":"181"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"26"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"3"}],"units":"Participants"}],"description":"Duration of response (DOR) for any confirmed RECIST CR or PR measured from the date of the first occurrence of a response until the first occurrence of progressive disease (PD) per RECIST. For patients who continued treatment post-progression, the first date of progression was used for the analysis. Any patients with an ongoing response were censored at the date of the last post-baseline scan. Complete response (CR) is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm. Partial response (PR) is at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of longest diameter.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with a deleterious BRCA mutation detected in their tumor.","id":"OG000","title":"Part 1: tBRCA"},{"description":"Patients without a BRCA mutation in their tumor, but have high LOH.","id":"OG001","title":"Part 1: Non-tBRCA LOH+"},{"description":"Patients without a BRCA mutation in their tumor, but have low LOH.","id":"OG002","title":"Part 1: Non-tBRCA LOH-"},{"description":"Patients without a BRCA mutation in their tumor, and have unknown LOH due to missing results and/or failed test result(s).","id":"OG003","title":"Part 1: Non-tBRCA LOH Unknown"},{"description":"Patients with a deleterious BRCA mutation detected in their tumor.","id":"OG004","title":"Part 2: tBRCA"},{"description":"Patients without a BRCA mutation in their tumor, but have high LOH.","id":"OG005","title":"Part 2: Non-tBRCA LOH+"},{"description":"Patients without a BRCA mutation in their tumor, but have low LOH.","id":"OG006","title":"Part 2: Non-tBRCA LOH-"},{"description":"Patients without a BRCA mutation in their tumor, and have unknown LOH due to missing results and/or failed test result(s).","id":"OG007","title":"Part 2: Non-tBRCA LOH Unknown"}],"paramType":"MEDIAN","populationDescription":"Efficacy population by HRD subgroups. The overall number of patients analyzed includes only patients with confirmed RECIST CR or PR.","reportingStatus":"POSTED","timeFrame":"Assessments every 8 weeks from C1D1 until disease progression, death or withdrawal of consent. After 18 months on study, assessments every 16 weeks. Total follow-up was up to approximately 3 years.","title":"Duration of Response Per RECIST v1.1","type":"SECONDARY","unitOfMeasure":"Days"}